RecruitingNCT04318366

COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor

Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response

Sponsor

Università Vita-Salute San Raffaele

Enrollment

6,000 participants

Start Date

Mar 19, 2020

Study Type

OBSERVATIONAL

Conditions

Coronavirus Infections

Summary

Collection and analysis of demographic, clinical, radiographic and laboratory characteristics of CoViD-19 patients to identify predictors of disease severity, mortality and treatment response, and to identify subgroup of patients that might benefit from specific therapeutic interventions

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a comprehensive registry and biobank of patients who were admitted to hospital with COVID-19 (caused by the SARS-CoV-2 virus). During the early phase of the pandemic and beyond, there was an urgent need to understand how the virus affects different people — why some have mild disease while others develop severe complications, what biological factors predict outcomes, and how treatments work. By collecting detailed clinical information and biological samples (blood, respiratory samples), this registry will serve as a platform for numerous research questions. Participants include both patients with confirmed COVID-19 and those with a strong clinical and radiological picture of COVID-19 even if the laboratory test was negative. The registry tracks treatment responses, outcomes, and long-term effects of the disease. You may be eligible if you: - Are 18 years of age or older - Were admitted to the hospital with laboratory-confirmed SARS-CoV-2, OR - Were admitted with clinical and radiological features highly suggestive of COVID-19 (even with a negative test), OR - Were discharged from an emergency department with a positive SARS-CoV-2 test There are no exclusion criteria — this registry is open to all eligible hospitalized patients. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational Study

Not required

Locations(13)

Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -

Milan, Lombardy, Italy

Department of Internal Medicine - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute

Milan, Lombardy, Italy

Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute

Milan, Lombardy, Italy

Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Nephrology Unit - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute

Milan, Lombardy, Italy

Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute

Milan, Lombardy, Italy

Università Vita-Salute San Raffaele

Milan, Mi, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04318366

Related Trials

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT0663128717 locations

In-depth Immunological Investigation of COVID-19.

NCT043275701 location

Study of the Incidence of SARS-CoV-2 Infection (COVID-19)

NCT044295941 location